Breakthrough in cancer treatment: China approves PADCEV for advanced urothelial cancer
China’s National Medical Products Administration (NMPA) has granted approval for PADCEV (enfortumab vedotin) to treat locally advanced or metastatic urothelial cancer (la/mUC) in adult patients. This significant decision follows prior treatments with platinum-containing chemotherapy and programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors. The approval marks a pivotal development in the fight against […]